Alpine Immune Sciences Announces $48 Million Series A Financing to Support Discovery and Development of the Next Generation of Immunotherapies
Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake
